GlassScriptPhysician profile
Ashley N Rees
NPI 1063977627
$2,997.20
in general payments reported to CMS, 2019-2025
20 companies · $815 in 2025
The $815 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $541 · 2023: $460 · 2024: $897 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $708.93 | 2022-2025 | |
| Amgen INC. | $557.90 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $333.93 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $187.46 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $154.60 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $132.49 | 2021-2024 | Wainua, Andexxa, Farxiga |
| Boston Scientific Corporation | $130.24 | 2022-2024 | Watchman Access System |
| Novo Nordisk INC | $125.07 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $117.24 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $109.87 | 2024-2025 | Amvuttra |
| Pfizer INC. | $103.80 | 2021-2023 | |
| Abbott Laboratories | $94.56 | 2024-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.77 | 2024-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.05 | 2021-2022 | |
| Amarin Pharma, INC. | $32.95 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $29.05 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $27.89 | 2025 | Evkeeza |
| Irhythm Technologies, INC. | $24.65 | 2022 | |
| Edwards Lifesciences Corporation | $22.91 | 2021 | |
| Medtronic, INC. | $18.84 | 2024 | Linq II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.